Protagonist Therapeutics Stock Surges 45% On Positive Phase 2b Study Results

(RTTNews) - Protagonist Therapeutics, Inc. (PTGX) closed trading at $55.95, up 45.40 percent or $17.41 during Monday's trading, after announcing positive topline results from its ANTHEM-UC Phase 2b study of icotrokinra.

The stock opened at $50.08 and has traded between $48.50 and $57.97, compared to a previous close of $38.35 on the Nasdaq. Current volume is 3.83 million shares, significantly above the average volume of 725,662. The stock's 52-week range is $24.22 to $57.97.

The investigational oral peptide, developed in collaboration with Johnson & Johnson, met its primary endpoint of clinical response in all dose groups for adults with moderately to severely active ulcerative colitis. The study also showed meaningful improvements over placebo in clinical remission, symptomatic remission, and endoscopic improvement at Week 12.